06.02.23 -- From Biggest Pharma To Rare Disease Start-Up

New salary transparency laws are being enacted by a growing number of states, and more transparency is needed to address existing inequities. Is it possible to be too transparent?

The service provider selection process is a complicated one. Many factors come into play during this process. One critical factor is undoubtedly the presence of preferred provider agreements. Companies can spend a great deal of time negotiating these agreements, and their presence, or lack thereof, can make or break which CROs are shortlisted or awarded a Phase 1 study.

Martin Mackay’s journey from Pfizer executive to founding and leading a rare disease biotech is a reflection of the industry’s evolution from a small molecule powerhouse to multimodal biotech.